248 related articles for article (PubMed ID: 30006034)
1. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
Liguori C; Stefani A; Ruffini R; Mercuri NB; Pierantozzi M
Parkinsonism Relat Disord; 2018 Dec; 57():80-81. PubMed ID: 30006034
[No Abstract] [Full Text] [Related]
2. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
[TBL] [Abstract][Full Text] [Related]
3. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
[TBL] [Abstract][Full Text] [Related]
4. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
5. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
Bianchi MLE; Riboldazzi G; Mauri M; Versino M
Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
[TBL] [Abstract][Full Text] [Related]
6. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
7. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
9. Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study.
Santos García D; Cabo López I; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Paz González JM; Alonso Losada MG; Gonzalez Palmás MJ; Cores Bartolomé C; Martínez Miró C
Neurol Sci; 2022 Apr; 43(4):2537-2544. PubMed ID: 34554335
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
Schrempf W; Fauser M; Wienecke M; Brown S; Maaß A; Ossig C; Otto K; Brandt MD; Löhle M; Schwanebeck U; Graehlert X; Reichmann H; Storch A
Eur J Neurol; 2018 Apr; 25(4):672-679. PubMed ID: 29322594
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Abdelalem Aziz Ahmed M
F1000Res; 2019; 8():2078. PubMed ID: 32431802
[No Abstract] [Full Text] [Related]
12. Safinamide in the treatment of Parkinson's disease.
Müller T
Neurodegener Dis Manag; 2020 Aug; 10(4):195-204. PubMed ID: 32648512
[TBL] [Abstract][Full Text] [Related]
13. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Alborghetti M; Nicoletti F
Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
15. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
[TBL] [Abstract][Full Text] [Related]
16. Safinamide for the treatment of Parkinson's disease.
deSouza RM; Schapira A
Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
[TBL] [Abstract][Full Text] [Related]
17. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Cattaneo C; Kulisevsky J; Tubazio V; Castellani P
Adv Ther; 2018 Apr; 35(4):515-522. PubMed ID: 29542008
[TBL] [Abstract][Full Text] [Related]
18. Safinamide: a new hope for Parkinson's disease?
Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
[TBL] [Abstract][Full Text] [Related]
19. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]